





UCI 16-55
Phase 1b, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma (Bota)

NRG BN001
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma (Kong)

NRG BN003**
Ph III Trial of observation versus irradiation for a gross totally resected grade II meningioma (Kong)

THERAPEUTIC 1ST LINE

BRAIN CANCER

THERAPEUTIC 2ND LINE

UCI 16-56**
Ph II Study of Optune in Bevacizumab-Naïve Subjects w/ Recurrent WHO grade III Malignant Astrocytoma (Bota)

UCI 17-35**
Ph II Trial of DSP-7888 Dosing Emulsion Combo w/ Bev vs Bev Alone for Glioblastoma (Kong)

UCI 14-58
Phase 1, Multicenter, Open-Label, Dose-Escalation, Combination Study of Marizomib and Bevacizumab in Bevacizumab-Naïve Subjects with WHO Grade IV Malignant Glioma Followed by Phase 2 Studies of Single Agent Marizomib and Combination Marizomib and Bevacizumab (Bota)

RTOG 3503
Phase II Trial of Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma (Kong)

ECOG-EAY131
Molecular Analysis for Therapy Choice – MATCH (Seery)

SWOG S1609
Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors – DART (Bota)

UCI 16-22
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflomithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur after Irradiation and Adjuvant Temozolomide Chemotherapy (Bota)

UCI 15-99
Open-Label, Non-Randomized, Phase 2 Study Evaluating Efficacy and Safety of PQR309 in Patients with Relapsed or Refractory Primary CNS Lymphoma (Bota)

ALLIANCE A071401
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations (Carrillo)

UCI 13-14
Randomized, Double-blinded, Placebo-controlled Phase 2 study of (ERC1671 + GM-CSF + Cyclophosphamide) + Bevacizumab vs. (Placebo Injection + Placebo pill) + Bevacizumab in treatment of recurrent/progressive GBM & gliosarcoma patients (WHO grade IV malignant gliomas) (Bota)

UCI 15-35**
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent GBM or Anaplastic Astrocytoma (Bota)